The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization.
The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization.
复制标题
改良实体瘤疗效评价标准（RECIST）比RECIST 1.1在肝细胞癌经动脉放射栓塞治疗中的预后更准确。
DOI：
10.5009/gnl19197
复制
发表时间：
2020-11-15
期刊：
影响因子：
3.4
通讯作者：
Kim SU
中科院分区：
文献类型：
--
作者：
Lee JS;Choi HJ;Kim BK;Park JY;Kim DY;Ahn SH;Han KH;Baek SE;Chung YE;Park MS;Kim MJ;Rhee H;Kim SU
实体瘤疗效评价标准（RECIST）1.1和改良RECIST（mRECIST）标准已用于评估肝细胞癌（HCC）患者的治疗缓解。我们研究了哪种标准能更好地预测接受经动脉放射性栓塞（TARE）治疗的HCC患者的生存率。回顾性分析了2012年至2017年期间接受TARE治疗的102例不可切除肝内HCC患者。在1、3和6个月时通过mRECIST和RECIST 1.1评价TARE后的治疗缓解。应答者定义为根据每项标准完全或部分应答的患者。83名男性和19名女性的中位年龄为64.3岁。中位甲胎蛋白和脱-γ-羧基凝血酶原水平分别为37.1 ng/mL和1，780.0 mAU/mL。中位最大肿瘤大小为8.3 cm，36例患者（35.3%）观察到多发性肿瘤。随访期间（中位数20.7个月），21例患者（20.6%）死亡，平均生存时间为55.5个月。6个月时累积生存率为96.1%，12个月时为89.3%。TARE后1、3和6个月时，根据mRECIST定义的应答者的生存结局优于无应答者（1个月时风险比[HR]=5.736，p=0.008; 3个月时HR=3.145，p=0.022; 6个月时HR=2.887，p=0.061）。按RECIST 1.1定义的应答者和无应答者的生存率相似（均p>0.05）。在接受TARE治疗的HCC患者中，使用mRECIST进行的缓解评价比使用RECIST 1.1进行的缓解评价更准确。
The Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) criteria have been used to assess treatment responses for hepatocellular carcinoma (HCC) patients. We investigated which criteria provides better survival predictions in HCC patients treated with transarterial radioembolization (TARE). In total, 102 patients with unresectable intrahepatic HCC, who were treated with TARE between 2012 and 2017, were reviewed retrospectively. The treatment response after TARE was evaluated at 1, 3, and 6 months by the mRECIST and RECIST 1.1. Responders were defined as patients with complete or partial responses by each criterion. The median age of 83 men and 19 women was 64.3 years. The median alpha-fetoprotein and des-gamma-carboxy prothrombin levels were 37.1 ng/mL and 1,780.0 mAU/mL, respectively. The median maximal tumor size was 8.3 cm, and multiple tumors were observed in 36 patients (35.3%). During the follow-up period (median, 20.7 months), 21 patients (20.6%) died, with a mean survival time of 55.5 months. The cumulative survival rate was 96.1% at 6 months and 89.3% at 12 months. Responders, defined by the mRECIST at 1, 3, and 6 months after TARE, showed better survival outcomes than nonresponders (hazard ratio [HR]=5.736, p=0.008 at 1 month; HR=3.145, p=0.022 at 3 months, and HR=2.887, p=0.061 at 6 months). The survival rates of responders and nonresponders defined by the RECIST 1.1 were similar (all p>0.05). Response evaluations that use the mRECIST provide more accurate prognoses than those that use the RECIST 1.1 in HCC patients treated with TARE.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
5.1
作者：
McGlynn KA;Petrick JL;London WT
通讯作者：
London WT
影响因子：
25.7
作者：
Kim, Beom Kyung;Kim, Seung Up;Han, Kwang-Hyub
通讯作者：
Han, Kwang-Hyub
影响因子：
13.5
作者：
Riaz, Ahsun;Gabr, Ahmed;Salem, Riad
通讯作者：
Salem, Riad
影响因子：
11.5
作者：
Kim, Beom Kyung;Kim, Seung Up;Chon, Chae Yoon
通讯作者：
Chon, Chae Yoon